Spontaneous subarachnoid hemorrhage of unknown origin: hospital course and long-term clinical and angiographic follow-up

Ali M. Elhadi, MD, PhD,1,2 Joseph M. Zabramski, MD,1,3 Kaith K. Almefty, MD,1 George A. C. Mendes, MD,2 Peter Nakaji, MD,1 Cameron G. McDougall, MD,1 Felipe C. Albuquerque, MD,1 Mark C. Preul, MD,2 and Robert F. Spetzler, MD1

1Division of Neurological Surgery; 2Neurosurgical Research Laboratory, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix; and 3Division of Neurological Surgery, Scottsdale Healthcare Osborn, Scottsdale, Arizona

OBJECT Hemorrhagic origin is unidentifiable in 10%–20% of patients presenting with spontaneous subarachnoid hemorrhage (SAH). While the patients in such cases do well clinically, there is a lack of long-term angiographic follow-up. The authors of the present study evaluated the long-term clinical and angiographic follow-up of a patient cohort with SAH of unknown origin that had been enrolled in the Barrow Ruptured Aneurysm Trial (BRAT).

METHODS The BRAT database was searched for patients with SAH of unknown origin despite having undergone two or more angiographic studies as well as MRI of the brain and cervical spine. Follow-up was available at 6 months and 1 and 3 years after treatment. Analysis included demographic details, clinical outcome (Glasgow Outcome Scale, modified Rankin Scale [mRS]), and repeat vascular imaging.

RESULTS Subarachnoid hemorrhage of unknown etiology was identified in 57 (11.9%) of the 472 patients enrolled in the BRAT study between March 2003 and January 2007. The mean age for this group was 51 years, and 40 members (70%) of the group were female. Sixteen of 56 patients (28.6%) required placement of an external ventricular drain for hydrocephalus, and 4 of these subsequently required a ventriculoperitoneal shunt. Delayed cerebral ischemia occurred in 4 patients (7%), leading to stroke in one of them. There were no rebleeding events. Eleven patients were lost to follow-up, and one patient died of unrelated causes. At the 3-year follow-up, 4 (9.1%) of 44 patients had a poor outcome (mRS > 2), and neurovascular imaging, which was available in 33 patients, was negative.

CONCLUSIONS Hydrocephalus and delayed cerebral ischemia, while infrequent, do occur in SAH of unknown origin. Long-term neurological outcomes are generally good. A thorough evaluation to rule out an etiology of hemorrhage is necessary; however, imaging beyond 6 weeks from ictus has little utility, and rebleeding is unexpected.

http://thejns.org/doi/abs/10.3171/2014.10.JNS14175

KEY WORDS angiographically negative; subarachnoid hemorrhage; BRAT; angiographic follow-up; hospital stay; vascular disorders; SAH of unknown origin
well documented, the results of long-term angiographic follow-up are unknown. We undertook this study to examine long-term clinical and angiographic follow-up in patients with SAH of unknown etiology who had been identified as part of the Barrow Ruptured Aneurysm Trial (BRAT).17,24

**Methods**

Between March 2003 and January 2007, a total of 500 patients consented to participate and were enrolled in the Barrow Ruptured Aneurysm Trial (BRAT). Consent was erroneously obtained in 28 patients, leaving 472 patients eligible for analysis. Reasons for consent errors included events such as hemorrhage more than 14 days before presentation, age exclusions, and the ultimate determination that SAH had been caused by trauma or that SAH had not occurred at all. A prospectively collected database of the 472 patients was searched for those with no identifiable source of the hemorrhage during their initial hospitalization. The BRAT is a prospective, randomized, controlled study designed to compare the results of surgical clipping versus those of endovascular coiling in the treatment of ruptured intracranial aneurysms. A description of the study, as well as outcome data at 1 and 3 years, has been published.17,24 Briefly, all patients between the ages of 18 and 80 years who had been admitted to the intensive care unit with acute nontraumatic SAH (diagnosed by CT or lumbar puncture) were eligible to participate and were included if they or their health care decision surrogate consented. Patients with traumatic SAH and those presenting to the hospital more than 14 days after hemorrhage were excluded. To maximize the comprehensive nature of the BRAT, all patients with diagnostically proven SAH were enrolled and continued to be tracked even if no source of hemorrhage was ever identified.

After enrollment, all patients received the same protocol of care. Initial evaluation included CT angiography (CTA) or conventional digital subtraction angiography (DSA). The latter was performed in all patients whose CTA was negative for the source of the SAH. If no source for the hemorrhage was found on admission imaging, angiography was repeated 1 week later. Patients in these cases also underwent MRI and MR angiography (MRA) of the brain and cervical spine. If no responsible lesion was detected during the initial hospitalization, patients underwent outpatient follow-up vascular imaging (CTA, MRA, or catheter-based angiography) at 4–6 weeks post-hemorrhage. For the purposes of the present study, only those patients in whom both the inpatient and the early outpatient vascular imaging studies failed to reveal an aneurysm or other vascular abnormality were considered to have no identifiable source of SAH.

A complete admission history, a physical, and standard screening laboratory work were performed in all patients. The Glasgow Coma Scale score, Hunt and Hess (HH) grade, and Fisher grade were calculated on admission. Independent neuroradiologists analyzed all imaging data. A dedicated research nurse practitioner acted as the study coordinator, monitored patient accrual and randomization, and was responsible for collecting follow-up data and assessing modified Rankin Scale (mRS) and Glasgow Outcome Scale (GOS) scores. Patients were asked to return for follow-up at 6 months, 1 year, and 3 years after treatment. At the 3-year follow-up visit, patients were asked to undergo repeat angiographic evaluation; the type of imaging performed (DSA, CTA, or MRA) was left to the discretion of the treating physician.

**Data Analysis**

All admission head CT scans were reviewed, and patients were assigned to 1 of 3 SAH groups: 1) the CT was negative (CTN), but SAH was confirmed by lumbar puncture; 2) classic hemorrhage pattern consistent with aneurysmal rupture; and 3) perimesencephalic hemorrhage (PMH), which was defined according to published criteria20,21 and included a focus of SAH ventral to the brainstem with limited or no evidence of hemorrhage in the basal, interhemispheric, or Sylvian cisterns. Patients with no hemorrhage detected on CT scans but who had xanthochromia on lumbar taps were classified as having CTN SAH. The extent of SAH on admission CT was graded using a modified Fisher scale (Table 1), with intraventricular hemorrhage (IVH) documented separately as present or absent.6,15 Delayed cerebral ischemia was defined as the occurrence of local neurological impairment or a decrease of at least 2 points on the Glasgow Coma Scale not attributed to other causes by means of clinical assessment, CT or MRI of the brain, and appropriate laboratory studies.27 Functional status was based on GOS and mRS scores.2,13

**Statistical Analysis**

Demographic data and bleeding patterns were analyzed using descriptive statistical analysis, outcomes for bleeding pattern groups were compared using a t-test, and length of hospital stay (LOS) was analyzed using the Mann-Whitney U-test. Regression statistics and ANOVA were used for evaluating multivariate analysis. Statistical significance was determined by p < 0.05.

**Results**

Among the 472 patients eligible for analysis, 57 patients had no source of hemorrhage identified during their initial hospitalization. One of these patients, a 67-year-old woman with a Fisher Grade 2 hemorrhage, had a small (2–3 mm) basilar trunk aneurysm identified on CTA during an outpatient follow-up 6 weeks after hemorrhage. The aneurysm was clipped without incident.

In the remaining 56 (11.9%) patients, no source of hemorrhage was identified during their initial inpatient or outpatient evaluations. The mean age of this group was 51.3 years (range 19–78 years). There were 39 women and 17

---

**TABLE 1. Modified Fisher scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>CT Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No evidence of SAH</td>
</tr>
<tr>
<td>2</td>
<td>Focal or diffuse, thin SAH</td>
</tr>
<tr>
<td>3</td>
<td>Focal or diffuse, thick SAH</td>
</tr>
<tr>
<td>IVH</td>
<td>Present or absent</td>
</tr>
</tbody>
</table>
men for a female/male ratio of 2.3:1. None of the patients had previously had an SAH, intracranial aneurysm, or arteriovenous malformation (AVM). Five patients had a history of atherosclerotic disease, 6 had diabetes mellitus, and 2 had hematological disorders (thrombocytopenia).

The hemorrhage pattern on admission CT was classic in 32 patients (57%), perimesencephalic in 13 (23%), and negative (positive on lumbar puncture) in 11 patients (20%; Table 2). The majority of patients (47 [83.9%]) presented with an HH grade of I or II, whereas only 9 (16.1%) had an HH grade of III. None of the patients had presented with an HH grade of IV or V.

The LOS for the 56 patients ranged from 2 to 27 days with a mean ± standard deviation of 9.5 ± 5.2 days (median 8 days, interquartile range [IQR] 5.5 days). Sixteen patients showed evidence of IVH, and 13 of them (81.3%) stayed in the hospital for 10 or more days. Of the remaining 40 patients without evidence of IVH, only 7 (17.5%) stayed in the hospital for 10 or more days. The average LOS for patients with IVH was 14.68 ± 5.6 days (median 14.5 days, IQR 7 days), compared with 7.5 ± 3.37 days (median 7 days, IQR 2 days) for those without IVH; however, this difference did not reach statistical significance. Patients who presented with an HH grade of I or II had an average LOS of 8.65 ± 5.1 days (median 7 days, IQR 3 days), compared with 14 ± 2.9 days (median 15 days, IQR 5.5 days) for those who presented with an HH grade of III (p = 0.0007). For the patients who had a Fisher grade of 1 or 2 on presentation, the average LOS was 7.36 ± 3.5 days (median 7 days, IQR 2 days), while those who had a Fisher grade of 3 stayed 13.5 ± 6.5 days (median 13 days, IQR 7.5 days; p < 0.0001).

Delayed cerebral ischemia occurred in 4 patients (7%). All four of these patients had a classic hemorrhage pattern on admission CT. Initial treatment consisted of hypervolemia and hypertension therapy; 2 patients (3.6%) required endovascular treatment (angioplasty and/or intraarterial infusion). Deficits resolved in all 4 patients; however, 1 patient had a diffusion-positive stroke documented on MRI in the posterior cerebral artery distribution (Fig. 1).

Sixteen patients (28.6%) required placement of an external ventricular drain (EVD) for clinical or CT evidence of hydrocephalus, and 4 of these patients subsequently required placement of a ventriculoperitoneal (VP) shunt. Three of the 4 patients who required a shunt had a classic hemorrhage pattern, and 1 had a PMH. Placement of an EVD was significantly more likely in patients with a classic hemorrhage pattern (p = 0.0028; Table 3) and in those with an IVH (p < 0.0001; Table 4). A shunt was removed after 48 months in 1 patient because hydrocephalus and CSF overdrainage resolved; this patient had a classic SAH pattern on initial presentation.

Overall outcome was favorable among those who presented with no identifiable SAH source. No deaths occurred during the initial hospitalization. Fifty-two patients (93%) were discharged to home, 4 (7%) to inpatient rehabilitation, and none to a skilled nursing facility. Long-term outcome scores (GOS and mRS) were available in 45 of 56 patients (Table 5), as 10 patients were lost to follow-up and 1 patient died of unrelated causes at 4 months after treat-

---

**TABLE 2. Hemorrhage pattern and clinical grade in 56 patients**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CTN SAH</th>
<th>PMH</th>
<th>Classic SAH</th>
<th>IVH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age in yrs</td>
<td>49</td>
<td>54</td>
<td>51</td>
<td>55</td>
</tr>
<tr>
<td>Fisher grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>11 (100)</td>
<td></td>
<td>11 (100)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13 (100)</td>
<td>12 (38)</td>
<td>20 (62)</td>
<td>13/20 (65)</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>3/25 (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HH grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>5 (45)</td>
<td>2 (15)</td>
<td>10 (31)</td>
<td>2/17 (12)</td>
</tr>
<tr>
<td>II</td>
<td>6 (55)</td>
<td>11 (85)</td>
<td>13 (41)</td>
<td>8/30 (27)</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td>9 (28)</td>
<td></td>
<td>6/9 (67)</td>
</tr>
<tr>
<td>IV-V</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total no.</td>
<td>11 (20)</td>
<td>13 (23)</td>
<td>32 (57)</td>
<td>16 (29)</td>
</tr>
</tbody>
</table>

---

*Placement of an EVD was significantly more likely in patients with a classic hemorrhage pattern (p = 0.0028).*

---

**FIG. 1.** Diffusion-weighted MR image demonstrating a left posterior cerebral artery ischemic stroke due to cerebral vasospasm in a patient with no identifiable source of SAH.
A. M. Elhadi et al.

TABLE 4. Intraventricular hemorrhage and EVD or VP shunt placement among 56 patients with no identifiable SAH source

<table>
<thead>
<tr>
<th>IVH (no.)</th>
<th>No. w/ EVD</th>
<th>No. w/ VP Shunt</th>
</tr>
</thead>
<tbody>
<tr>
<td>With (16)</td>
<td>13*</td>
<td>3†</td>
</tr>
<tr>
<td>Without (40)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Placement of an EVD was significantly more likely in patients with an IVH (p < 0.0001).
† Placement of a VP shunt was significantly more likely in patients with an IVH (p = 0.0329).

Discussion

The evaluation of clinical outcome in patients with an SAH without an identifiable source has been reported; however, data on the long-term angiographic follow-up in this group of patients have been lacking. The ongoing BRAT provided an opportunity to prospectively study this group of patients. The BRAT enrolled and prospectively followed all patients with angiographically proven SAH, even if no source of hemorrhage was ever identified. In the initial cohort of 472 patients enrolled in the BRAT, 17, and DSA in 1 patient. All imaging studies were negative for aneurysm, AVM, or other vascular abnormality and were unchanged from the discharge angiograms.

The 10 patients lost to follow-up included 8 females and 2 males whose mean age was 43 ± 13 years. On admission, 5 of these patients had an HH grade of I, and 5 had an HH grade of II. Six patients (60%) had a classic bleeding pattern, 2 (20%) had PMH, and 2 (20%) had CTN SAH. The mean LOS for this subgroup was a 9 ± 1.4 days (median 8 days, IQR 6 days). Three patients required placement of an EVD, but none required a VP shunt. All 10 patients were discharged to home, when 8 patients had GOS Score 5 and 2 had GOS Score 4.

Ischemia, hydrocephalus, and rebleeding have been reported. In a series of 71 patients with angiographically negative SAH, Canhão et al. reported that 3% of patients rebled, 4% developed delayed cerebral ischemia, and 3% had hydrocephalus that required placement of a shunt. Duong and coworkers described outcome at hospital discharge in a series of 87 patients with angiographically negative SAH. They reported rebleeding in 4%, delayed ischemia in 4%, and hydrocephalus in 14%, with 3% requiring placement of a shunt. There were 2 deaths (2%) related to rebleeding, which the authors suspected were attributable to undiagnosed aneurysms. In a study of 89 patients with angiogram-negative SAH, Whiting et al. reported that 25% had early hydrocephalus requiring ventriculostomy and that 13% required placement of a shunt. Symptomatic vasospasm was reported in 4 patients (4%), 2 of whom developed associated infarctions. Three patients (3%) died, and each of these patients was moribund on presentation.

No deaths and no rebleeding episodes occurred in the present study. Hydrocephalus requiring ventriculostomy was present in 28% of patients. Hydrocephalus was significantly more common in patients with the classic pattern of hemorrhage and in those with IVH (Tables 3 and 4). Four patients in this study, 3 with the classic pattern of hemorrhage and 1 with PMH, could not be weaned from their ventriculostomy and required placement of a VP shunt.

Delayed cerebral ischemia due to vasospasm occurred in 4 patients (7%) in this series and resulted in permanent ischemic changes in 1 patient (1.8%). In the literature, the terms “symptomatic vasospasm” and “delayed cerebral ischemia” are often used interchangeably. Acknowledging that there may be some difference in the definitions for these terms, we found that the incidence of delayed cerebral ischemia and/or symptomatic vasospasm in patients with no identifiable cause of SAH ranges between 0% and 6%. Several studies have shown that the most important risk factor for the development of delayed cerebral ischemia and/or symptomatic vasospasm is the amount of blood in the subarachnoid space.

Hemorrhage volumes tend to be greater in the classic pattern of SAH, and, not surprisingly, delayed cerebral ischemia occurs primarily in patients with this type of SAH. Vasospasm is rare in patients with PMH, and when present, it tends to resolve without significant neurologi
cal deficits. Canhão et al. reported a 5.7% incidence of delayed ischemic deficits due to vasospasm in 35 patients with angiographically negative SAH with the classic hemorrhage pattern and no incidence in the PMH group. In a recent review of this topic, Gross and colleagues noted that for patients with the classic hemorrhage pattern the rate of delayed ischemic deficits was 9.7%, while in patients with PMH the rate was 2.4%. In the present study, delayed ischemic deficits occurred only in patients with the classic pattern of hemorrhage.

Clinical outcome following SAH with no identifiable source also appears to be related to the volume and type of hemorrhage, with worse outcomes reported for patients with the classic diffuse pattern of hemorrhage. In a series of 94 patients, Hui et al. noted that ultimately only 76% of patients with classic hemorrhage achieved
<table>
<thead>
<tr>
<th>Score</th>
<th>GOS score</th>
<th>Discharge</th>
<th>6 Mos</th>
<th>1 Yr</th>
<th>3 Yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CTN</td>
<td>PMH</td>
<td>Classic</td>
<td>CTN</td>
<td>PMH</td>
</tr>
<tr>
<td>1–2</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>1 (2)</td>
<td>4 (9)</td>
<td>—</td>
<td>2 (5)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>4</td>
<td>8 (17)</td>
<td>7 (15)</td>
<td>14 (32)</td>
<td>9 (20)</td>
<td>9 (20)</td>
</tr>
<tr>
<td>5</td>
<td>3 (7)</td>
<td>3 (7)</td>
<td>4 (9)</td>
<td>8 (18)</td>
<td>8 (18)</td>
</tr>
<tr>
<td>mRS score</td>
<td>0</td>
<td>3 (7)</td>
<td>3 (7)</td>
<td>4 (9)</td>
<td>8 (18)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>3 (7)</td>
<td>5 (11)</td>
<td>6 (13)</td>
<td>1 (2)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>3 (7)</td>
<td>3 (7)</td>
<td>4 (9)</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>—</td>
<td>1 (2)</td>
<td>6 (13)</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>—</td>
<td>2 (4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>—</td>
<td>2 (4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>—</td>
<td>1 (3)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>9 (20)</td>
<td>11 (24)</td>
<td>25 (56)</td>
<td>9 (20)</td>
<td>11 (25)</td>
</tr>
<tr>
<td>Overall total</td>
<td>45</td>
<td>44</td>
<td>44</td>
<td>44</td>
<td>44</td>
</tr>
</tbody>
</table>
complete independent recovery, as compared with 97% of patients with PMH. We found a similar pattern in our patients: at 6 months posthemorrhage (Table 5), only 58% (n = 14) of the 24 patients with classic hemorrhage had recovered to an mRS score of 0 or 1, as compared with 95% (n = 19) of the 20 patients with CTN SAH or PMH. At 3 years posthemorrhage, the percentage of patients with an mRS score of 0 or 1 had increased to 79% (n = 19) in the group of 24 with classic hemorrhage, although there were still 3 patients (12.5%) with moderate disability requiring some help with activities of daily living.

A number of risk factors have been associated with an SAH whose source cannot be ascertained, including hypertension, chronic obstructive pulmonary disease, venous hypertension, diabetes, alcoholism, and drug abuse, but recurrent hemorrhage is rare, making a correlation difficult to establish. The absence of a clear explanation for hemorrhage in these patients raises concerns that they may harbor occult vascular lesions or may have an increased risk of developing aneurysms or other vascular malformations. Angiographic follow-up in this group has been limited in previous studies.

In Topcuoglu et al.’s series of 86 patients, follow-up angiography studies were obtained within the first 4 weeks after a patient’s initial bleed, and only 4 patients were found to have aneurysms that had not been diagnosed on initial angiography. All 4 patients had the classic pattern of bleeding, and the lesion was diagnosed on the second angiography (3 patients) or the third (1 patient), which was performed within the first 4 weeks postbleed. Jung and colleagues reported similar findings in their series, identifying an aneurysm in only 1 (1.5%) of 65 patients with PMH undergoing repeat 4-vessel angiography, versus 17 (46%) of 37 patients with a classic pattern of hemorrhage. Little et al. reported that repeat angiography performed between 1 and 6 weeks posthemorrhage demonstrated an
aneurysm in 5 (12%) of 42 patients with a classic pattern of hemorrhage, in 1 (7%) of 15 patients with PMH, and in no patients with CTN.

In the present study, we prospectively followed a cohort of 56 patients with SAH whose diagnostic workup was negative at 4–6 weeks posthemorrhage. Long-term outcome was available at 6 months, 1 year, and 3 years in 44 of 56 patients. No cases of delayed hemorrhage were identified in any patient in this group; however, 1 patient died of unrelated causes at 4 months, and data were unavailable for 10 patients lost to follow-up. Angiographic follow-up at 3 years was negative for aneurysm, AVM, or other vascular abnormalities in 33 of the 44 available patients; the remaining 11 patients declined requests for repeat angiographic evaluation.

Study Strengths and Limitations

The main strengths of this study are 1) the availability of long-term clinical and angiographic follow-up for patients with SAH whose source was unknown, 2) and the fact that the entire follow-up was prospectively performed as part of the BRAT, which included clinical evaluations at 6 months, 1 year, and 3 years and angiographic follow-up at 3 years. However, the study has 3 limitations: 1) it was limited to a relatively small number of patients (56 patients); 2) data analysis was undertaken retrospectively; and 3) 10 patients (18%) were lost to follow-up, and 11 of the 44 patients available for clinical follow-up declined to undergo additional imaging studies. While the size of the study population is limited, the results support conclusions reported by others that patients with SAH whose source is unknown, even those presenting with a classic diffuse pattern of hemorrhage, tend to have a good outcome.3,8,14

The potential for selection bias is an issue in any retrospective analysis but is limited in this cohort, as all patients were enrolled in the BRAT protocol at the time of their initial presentation and were prospectively monitored by a dedicated research nurse practitioner who acted as the study coordinator, monitored patient accrual, and was responsible for contacting patients for follow-up and for assessing mRS and GOS scores.

The loss of patients to follow-up can lead to significant bias in clinical outcome, particularly if these patients represent a subgroup with better or worse outcomes than those in the rest of the study population. Ten (18%) of 56 patients were lost to follow-up in the present study; all 10 were discharged to home. Although 3 patients in this group required placement of an EVD, none required a shunt. At discharge, 8 patients had a GOS score of 5, and 2 had a GOS score of 4. Assuming that the GOS scores remained static, inclusion of these 10 patients would not have significantly altered clinical outcome at 3 years: GOS Score 3, 4% versus 5%; GOS Score 4, 19% versus 18%; GOS Score 5, 78% versus 77%, respectively, for results with and without the additional 10 patients. Although delayed recurrent hemorrhage in patients with SAH of unknown etiology is considered rare, the possibility of such an event adversely affecting outcome in this group cannot be completely dismissed.

Finally, 11 of the 44 patients seen at the 3-year follow-up declined to undergo additional angiographic evaluation of any type. The lack of angiographic follow-up in these patients places some additional limits on the strength of our conclusions; however, none of these patients reported any signs or symptoms consistent with SAH.

Conclusions

The results of this study suggest that long-term angiographic follow-up beyond 6 weeks has little utility in patients with SAH of unknown etiology, regardless of the hemorrhage pattern, and that delayed rebleeding is an unexpected event. Although the clinical course of patients with SAH whose source is unknown is generally benign, vasospasm and hydrocephalus can occur, and close monitoring of patients who present with higher grade hemorrhages is indicated. Functional deficits occur primarily in patients with the classic pattern of hemorrhage and tend to improve over time.

References


Long-term follow-up for subarachnoid hemorrhage of unknown origin

J Neurosurg Volume 122 • March 2015 669
18. Pinto AN, Ferro JM, Canhão P, Campos J: How often is a perimesencephalic subarachnoid haemorrhage CT pattern caused by ruptured aneurysms? Acta Neurochir (Wien) 124:79–81, 1993

Author Contributions

Correspondence
Joseph M. Zabramski, c/o Neuroscience Publications, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013. email: neuropub@dignityhealth.org.